Fundraising FoxSiVEC Biotechnologies
Fort Collins, US · Founded 2022 · Delaware corporation · 1 known investors
Find your way into SiVEC Biotechnologies
Each arrow is one introduction. Sign up to fill in the first one.
Ask Tim Weelborg to introduce you to Darcy Mora
You →Tim · together at Colorado State University →Darcy
Sign up to find every way you can get introduced to SiVEC Biotechnologies
- Your email: who you already know at SiVEC Biotechnologies, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the SiVEC Biotechnologies team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
SiVEC Biotechnologies develops BactPac, a live biotherapeutic delivery platform that enables targeted delivery of nucleic acid therapies and gene editing therapies for clinical advancement. The company licenses its platform technology to pharmaceutical partners and pursues its own therapeutic pipeline in oncology and other disease areas.
Founders & leadership
SiVEC Biotechnologies was founded in 2022 by Lyndsey Linke, PhD.
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$3.3M disclosed across 1 round · 2025
▶$3.3MraisedSep 2025 · 3 investors · BiotechnologyRule 506(b)
- David SherrisDirector
- Darcy MoraExecutive Officer, Director
- Lyndsey LinkeExecutive Officer, Director
- Richard A. Freed IIIDirector
- Sibylle HauserDirector
- Offering amount
- $5.8M
- Amount sold
- $3.3M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $286.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $293.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does SiVEC Biotechnologies do?
- SiVEC Biotechnologies develops BactPac, a live biotherapeutic delivery platform that enables targeted delivery of nucleic acid therapies and gene editing therapies for clinical advancement. The company licenses its platform technology to pharmaceutical partners and pursues its own therapeutic pipeline in oncology and other disease areas.
- Who founded SiVEC Biotechnologies?
- SiVEC Biotechnologies was founded by Lyndsey Linke, PhD in 2022.
- Who are SiVEC Biotechnologies's investors?
- SiVEC Biotechnologies's investors include Colorado BioScience Association.
- How much funding has SiVEC Biotechnologies raised?
- SiVEC Biotechnologies has disclosed $3.3M raised across 1 round.
- Where is SiVEC Biotechnologies headquartered?
- SiVEC Biotechnologies is headquartered in Fort Collins, US.